Mode of action of adjuvants: Implications for vaccine safety and design

Biologicals

Volumn 38, Issue 5, 2010, Pages 594-601

  Mastelic, Béatris ^a   Ahmed, Sohail ^b   Egan, William M ^c   Del Giudice, Giuseppe ^b   Golding, Hana ^d   Gust, Ian ^e   Neels, Pieter ^f   Reed, Steven G ^g   Sheets, Rebecca L ^h   Siegrist, Claire Anne ^a   Lambert, Paul Henri ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^c PharmaNet Development Group Inc   (United States)

^d CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f Federal Agency for Medicines and Health Products   (Belgium)

^g INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^h U S PUBLIC HEALTH SERVICE   (United States)

Author keywords

Adjuvants; Mode of action of adjuvants; Vaccine; Vaccine safety

Indexed keywords

ADJUVANT; ALUMINUM; ALUMINUM POTASSIUM SULFATE; BCG VACCINE; CRYOPYRIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 33; LIPOSOME; MALARIA VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; PHOSPHORYL LIPID A; SAPONIN; TOLL LIKE RECEPTOR; VACCINE; VIROSOME;

ANTIBODY RESPONSE; AUTOIMMUNE DISEASE; CONFERENCE PAPER; CROSS PRESENTATION; CYTOKINE PRODUCTION; EMULSION; FLOW CYTOMETRY; HUMAN; IMMUNOPOTENTIATION; INNATE IMMUNITY; MALARIA; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; RISK ASSESSMENT; SCREENING TEST; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CHEMISTRY, PHARMACEUTICAL; COMMUNICABLE DISEASES; DRUG COMPOUNDING; DRUG DESIGN; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MARYLAND; MASS VACCINATION; PANDEMICS; PUBLIC HEALTH; SAFETY; UNITED STATES; VACCINES;

EID: 77956229043     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2010.06.002     Document Type: Conference Paper

References (47)

1. Brewer J.M., Conacher M., Satoskar A., Bluethmann H., Alexander J. In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to Freund's complete adjuvant, but continues to induce T helper 2 cytokine production. Eur J Immunol 1996, 26:2062-2066.
2. HogenEsch H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine 2002, 20(Suppl. 3):S34-S39.
3. Noe S.M., Green M.A., HogenEsch H., Hem S.L. Mechanism of immunopotentiation by aluminum-containing adjuvants elucidated by the relationship between antigen retention at the inoculation site and the immune response. Vaccine 2010, 28:3588-3594.
4. Kool M., Petrilli V., De Smedt T., Rolaz A., Hammad H., van Nimwegen M., et al. Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol 2008, 181:3755-3759.
5. Eisenbarth S.C., Colegio O.R., O'Connor W., Sutterwala F.S., Flavell R.A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008, 453:1122-1126.
6. Sutterwala F.S., Ogura Y., Flavell R.A. The inflammasome in pathogen recognition and inflammation. J Leukoc Biol 2007, 82:259-264.
7. Sutterwala F.S., Ogura Y., Szczepanik M., Lara-Tejero M., Lichtenberger G.S., Grant E.P., et al. Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 2006, 24:317-327.
8. Kool M., Soullie T., van Nimwegen M., Willart M.A., Muskens F., Jung S., et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 2008, 205:869-882.
9. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004, 5:987-995.
10. Reed S.G., Bertholet S., Coler R.N., Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 2009, 30:23-32.
11. O'Hagan D.T., De Gregorio E. The path to a successful vaccine adjuvant-'the long and winding road'. Drug Discov Today 2009, 14:541-551.
12. Baldridge J.R., Crane R.T. Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines. Methods 1999, 19:103-107.
13. Verstraeten T., Descamps D., David M.P., Zahaf T., Hardt K., Izurieta P., et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 2008, 26:6630-6638.
14. Giannini S.L., Hanon E., Moris P., Van Mechelen M., Morel S., Dessy F., et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006, 24:5937-5949.
15. Didierlaurent A.M., Morel S., Lockman L., Giannini S.L., Bisteau M., Carlsen H., et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009, 183:6186-6197.
16. Kensil C.R. Saponins as vaccine adjuvants. Crit Rev Ther Drug Carrier Syst 1996, 13:1-55.
17. Maloy K.J., Donachie A.M., Mowat A.M. Induction of Th1 and Th2 CD4+ T cell responses by oral or parenteral immunization with ISCOMS. Eur J Immunol 1995, 25:2835-2841.
18. Lipford G.B., Wagner H., Heeg K. Vaccination with immunodominant peptides encapsulated in Quil A-containing liposomes induces peptide-specific primary CD8+ cytotoxic T cells. Vaccine 1994, 12:73-80.
19. Windon R.G., Chaplin P.J., Beezum L., Coulter A., Cahill R., Kimpton W., et al. Induction of lymphocyte recruitment in the absence of a detectable immune response. Vaccine 2000, 19:572-578.
20. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001, 19:2673-2680.
21. Mosca F., Tritto E., Muzzi A., Monaci E., Bagnoli F., Iavarone C., et al. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci U S A 2008, 105:10501-10506.
22. Agger E.M., Rosenkrands I., Hansen J., Brahimi K., Vandahl B.S., Aagaard C., et al. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS One 2008, 3:e3116.
23. Lindenstrom T., Agger E.M., Korsholm K.S., Darrah P.A., Aagaard C., Seder R.A., et al. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J Immunol 2009, 182:8047-8055.
24. Kamath A.T., Rochat A.F., Christensen D., Agger E.M., Andersen P., Lambert P.H., et al. A liposome-based mycobacterial vaccine induces potent adult and neonatal multifunctional T cells through the exquisite targeting of dendritic cells. PLoS One 2009, 4:e5771.
25. Schoenen H., Bodendorfer B., Hitchens K., Manzanero S., Werninghaus K., Nimmerjahn F., et al. Cutting edge: Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate. J Immunol 2010, 184:2756-2760.
26. Siegrist C.A., Aspinall R. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol 2009, 9:185-194.
27. Ridge J.P., Fuchs E.J., Matzinger P. Neonatal tolerance revisited: turning on newborn T cells with dendritic cells. Science 1996, 271:1723-1726.
28. Kamath A.T., Rochat A.F., Valenti M.P., Agger E.M., Lingnau K., Andersen P., et al. Adult-like anti-mycobacterial T cell and in vivo dendritic cell responses following neonatal immunization with Ag85B-ESAT-6 in the IC31 adjuvant. PLoS One 2008, 3:e3683.
29. Sauce D., Larsen M., Fastenackels S., Duperrier A., Keller M., Grubeck-Loebenstein B., et al. Evidence of premature immune aging in patients thymectomized during early childhood. J Clin Invest 2009, 119:3070-3078.
30. Lazuardi L., Jenewein B., Wolf A.M., Pfister G., Tzankov A., Grubeck-Loebenstein B. Age-related loss of naive T cells and dysregulation of T-cell/B-cell interactions in human lymph nodes. Immunology 2005, 114:37-43.
31. Prelog M., Keller M., Geiger R., Brandstatter A., Wurzner R., Schweigmann U., et al. Thymectomy in early childhood: significant alterations of the CD4(+)CD45RA(+)CD62L(+) T cell compartment in later life. Clin Immunol 2009, 130:123-132.
32. Panda A., Qian F., Mohanty S., van Duin D., Newman F.K., Zhang L., et al. Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J Immunol 2010, 184:2518-2527.
33. Herndler-Brandstetter D., Schwaiger S., Veel E., Fehrer C., Cioca D.P., Almanzar G., et al. CD25-expressing CD8+ T cells are potent memory cells in old age. J Immunol 2005, 175:1566-1574.
34. Schwaiger S., Wolf A.M., Robatscher P., Jenewein B., Grubeck-Loebenstein B. IL-4-producing CD8+ T cells with a CD62L++(bright) phenotype accumulate in a subgroup of older adults and are associated with the maintenance of intact humoral immunity in old age. J Immunol 2003, 170:613-619.
35. Saurwein-Teissl M., Lung T.L., Marx F., Gschosser C., Asch E., Blasko I., et al. Lack of antibody production following immunization in old age: association with CD8(+)CD28(-) T cell clonal expansions and an imbalance in the production of Th1 and Th2 cytokines. J Immunol 2002, 168:5893-5899.
36. Squarcione S., Sgricia S., Biasio L.R., Perinetti E. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. Vaccine 2003, 21:1268-1274.
37. Saurwein-Teissl M., Zisterer K., Schmitt T.L., Gluck R., Cryz S., Grubeck-Loebenstein B. Whole virus influenza vaccine activates dendritic cells (DC) and stimulates cytokine production by peripheral blood mononuclear cells (PBMC) while subunit vaccines support T cell proliferation. Clin Exp Immunol 1998, 114:271-276.
38. Sun P., Schwenk R., White K., Stoute J.A., Cohen J., Ballou W.R., et al. Protective immunity induced with malaria vaccine, RTS, S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma. J Immunol 2003, 171:6961-6967.
39. Alonso P.L., Sacarlal J., Aponte J.J., Leach A., Macete E., Milman J., et al. Efficacy of the RTS, S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004, 364:1411-1420.
40. Kester K.E., Cummings J.F., Ofori-Anyinam O., Ockenhouse C.F., Krzych U., Moris P., et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS, S/AS01B and RTS, S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 2009, 200:337-346.
41. Bejon P., Lusingu J., Olotu A., Leach A., Lievens M., Vekemans J., et al. Efficacy of RTS, S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 2008, 359:2521-2532.
42. Cheng C., Gall J.G., Nason M., King C.R., Koup R.A., Roederer M., et al. Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization. J Virol 2010, 84:630-638.
43. Flatz L., Hegazy A.N., Bergthaler A., Verschoor A., Claus C., Fernandez M., et al. Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. Nat Med 2010, 16:339-345.
44. Mast T.C., Kierstead L., Gupta S.B., Nikas A.A., Kallas E.G., Novitsky V., et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 2010, 28:950-957.
45. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361:2209-2220.
46. Khurana S., Chearwae W., Castellino F., Manischewitz J., King L.R., Honorkiewicz A., et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med 2010, 2:15ra15.
47. Belkaid Y., Liesenfeld O., Maizels R.M. 99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: induction and control of regulatory T cells in the gastrointestinal tract: consequences for local and peripheral immune responses. Clin Exp Immunol 2010, 160:35-41.